Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure

2021 European Journal of Heart Failure 1,374 citations

Abstract

Abstract In this document, we propose a universal definition of heart failure (HF) as a clinical syndrome with symptoms and/or signs caused by a structural and/or functional cardiac abnormality and corroborated by elevated natriuretic peptide levels and/or objective evidence of pulmonary or systemic congestion. We also propose revised stages of HF as: At risk for HF (Stage A), Pre‐HF (Stage B), Symptomatic HF (Stage C) and Advanced HF (Stage D). Finally, we propose a new and revised classification of HF according to left ventricular ejection fraction (LVEF). This includes HF with reduced ejection fraction (HFrEF): symptomatic HF with LVEF ≤40%; HF with mildly reduced ejection fraction (HFmrEF): symptomatic HF with LVEF 41–49%; HF with preserved ejection fraction (HFpEF): symptomatic HF with LVEF ≥50%; and HF with improved ejection fraction (HFimpEF): symptomatic HF with a baseline LVEF ≤40%, a ≥10 point increase from baseline LVEF, and a second measurement of LVEF > 40%.

Keywords

Ejection fractionHeart failureMedicineCardiologyInternal medicineNatriuretic peptide

Related Publications

Baseline characteristics and treatment of patients in Prospective comparison of <scp>ARNI</scp> with <scp>ACEI</scp> to Determine Impact on Global Mortality and morbidity in Heart Failure trial (<scp>PARADIGM‐HF</scp>)

Aim To describe the baseline characteristics and treatment of the patients randomized in the PARADIGM‐HF (Prospective comparison of ARNi with ACEi to Determine Impact on Global ...

2014 European Journal of Heart Failure 167 citations

Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin‐converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM‐HF)

Aims Although the focus of therapeutic intervention has been on neurohormonal pathways thought to be harmful in heart failure (HF), such as the renin–angiotensin–aldosterone sys...

2013 European Journal of Heart Failure 439 citations

A trial to evaluate the effect of the sodium–glucose co‐transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA‐HF)

Background Sodium–glucose co‐transporter 2 (SGLT2) inhibitors have been shown to reduce the risk of incident heart failure hospitalization in individuals with type 2 diabetes wh...

2019 European Journal of Heart Failure 430 citations

Publication Info

Year
2021
Type
article
Volume
23
Issue
3
Pages
352-380
Citations
1374
Access
Closed

External Links

Citation Metrics

1374
OpenAlex

Cite This

Biykem Bozkurt, Andrew J.S. Coats, Hiroyuki Tsutsui et al. (2021). Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. European Journal of Heart Failure , 23 (3) , 352-380. https://doi.org/10.1002/ejhf.2115

Identifiers

DOI
10.1002/ejhf.2115